Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Huadong to Promote Impact’s PARP Inhibitor in China in $40 Million Agreement

publication date: Dec 22, 2023

Huadong Medicine will collaborate with Shanghai’s Impact Therapeutics to promote Impact’s Senaparib, a novel PARP inhibitor, in mainland China. Impact will receive $14 million upfront and up to $26 million in milestones. Huadong will receive promotion service fees on net sales. Impact will continue to be responsible for development, registration, manufacturing, supply and distribution of Senaparib. Earlier this year, Impact announced Senaparib met its primary endpoint in a China Phase III trial as a maintenance therapy for ovarian cancer following first-line platinum-based chemotherapy. Impact develops oncology medicines based on synthetic lethality. More details....

Stock Symbol: (SHZ: 000963)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here